CDH1 and breast carcinoma: Furthermore, and in accordance with previous studies [72,75], the pattern of E-cadherin expression differ between primary tumours and their lymph node metastases, reinforcing the concept that, during breast carcinoma progression, there is a dynamic and reversible modulation of the E-cadherin complex [4,76,77].